Kura Oncology Stock Price To Earnings To Growth
KURA Stock | USD 19.62 0.44 2.19% |
Kura Oncology fundamentals help investors to digest information that contributes to Kura Oncology's financial success or failures. It also enables traders to predict the movement of Kura Stock. The fundamental analysis module provides a way to measure Kura Oncology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kura Oncology stock.
Kura | Price To Earnings To Growth |
Kura Oncology Company Price To Earnings To Growth Analysis
Kura Oncology's PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Kura Price To Earnings To Growth Driver Correlations
Understanding the fundamental principles of building solid financial models for Kura Oncology is extremely important. It helps to project a fair market value of Kura Stock properly, considering its historical fundamentals such as Price To Earnings To Growth. Since Kura Oncology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Kura Oncology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Kura Oncology's interrelated accounts and indicators.
Click cells to compare fundamentals
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
Competition |
Kura Price Earnings To Growth Ratio
Price Earnings To Growth Ratio |
|
Based on the latest financial disclosure, Kura Oncology has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 100.0% higher than that of the company.
Kura Price To Earnings To Growth Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kura Oncology's direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kura Oncology could also be used in its relative valuation, which is a method of valuing Kura Oncology by comparing valuation metrics of similar companies.Kura Oncology is currently under evaluation in price to earnings to growth category among related companies.
Kura Fundamentals
Return On Equity | -0.37 | ||||
Return On Asset | -0.23 | ||||
Current Valuation | 1.12 B | ||||
Shares Outstanding | 76.18 M | ||||
Shares Owned By Insiders | 1.07 % | ||||
Shares Owned By Institutions | 98.93 % | ||||
Number Of Shares Shorted | 10.12 M | ||||
Price To Earning | (9.03) X | ||||
Price To Book | 3.73 X | ||||
EBITDA | (164.96 M) | ||||
Net Income | (152.63 M) | ||||
Cash And Equivalents | 450.26 M | ||||
Cash Per Share | 6.73 X | ||||
Total Debt | 17.2 M | ||||
Debt To Equity | 0.01 % | ||||
Current Ratio | 25.73 X | ||||
Book Value Per Share | 5.34 X | ||||
Cash Flow From Operations | (124.82 M) | ||||
Short Ratio | 11.66 X | ||||
Earnings Per Share | (2.08) X | ||||
Target Price | 30.25 | ||||
Number Of Employees | 142 | ||||
Beta | 0.87 | ||||
Market Capitalization | 1.54 B | ||||
Total Asset | 448.94 M | ||||
Retained Earnings | (721.44 M) | ||||
Working Capital | 397.22 M | ||||
Current Asset | 86.87 M | ||||
Current Liabilities | 5.05 M | ||||
Net Asset | 448.94 M |
About Kura Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kura Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kura Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kura Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Kura Oncology Investors Sentiment
The influence of Kura Oncology's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Kura. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Kura Oncology's public news can be used to forecast risks associated with an investment in Kura. The trend in average sentiment can be used to explain how an investor holding Kura can time the market purely based on public headlines and social activities around Kura Oncology. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Kura Oncology's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Kura Oncology's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Kura Oncology's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Kura Oncology.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Kura Oncology in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Kura Oncology's short interest history, or implied volatility extrapolated from Kura Oncology options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Kura Oncology Piotroski F Score and Kura Oncology Altman Z Score analysis. For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Complementary Tools for Kura Stock analysis
When running Kura Oncology's price analysis, check to measure Kura Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kura Oncology is operating at the current time. Most of Kura Oncology's value examination focuses on studying past and present price action to predict the probability of Kura Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kura Oncology's price. Additionally, you may evaluate how the addition of Kura Oncology to your portfolios can decrease your overall portfolio volatility.
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
Is Kura Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kura Oncology. If investors know Kura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kura Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.08) | Return On Assets (0.23) | Return On Equity (0.37) |
The market value of Kura Oncology is measured differently than its book value, which is the value of Kura that is recorded on the company's balance sheet. Investors also form their own opinion of Kura Oncology's value that differs from its market value or its book value, called intrinsic value, which is Kura Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kura Oncology's market value can be influenced by many factors that don't directly affect Kura Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kura Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kura Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kura Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.